Wastewater aeration is an important unit operation that provides dissolved oxygen for microorganisms in wastewater treatment. In this study, the impact of peracetic acid (PAA) dosing on wastewater aeration was assessed in terms of oxygen transfer, visual observation of bubble size changes, and evolution of dissolved oxygen from PAA (and HO) decomposition. Oxygen transfer coefficients improved with PAA concentrations of up to 7 mg/L, which was probably due to the smaller bubbles being formed from the aeration diffuser and evolution of small bubbles from PAA (and HO) decomposition. At a PAA concentration higher than 7 mg/L, the accumulation of acetate molecules to the gas-liquid interface of bubbles likely began to counteract the positive impact of bubble size decrease by increasing the mass transfer resistance of oxygen from bubbles to water. Finally, a continuous bench-scale primary effluent aeration experiment demonstrated that at a continuous PAA dosing of 1 mg/L, the air input by a compressor could be decreased by 54%, while keeping the oxygen level constant at approximately 1.5 mg/L. PAA dosing could be combined, for example, with aerated grit removal to enhance the primary effluent aeration together with additional benefits of partial disinfection and odor formation prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2166/wst.2023.262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Odorant production surges induced by exogenous oxidative stress: An overlooked risk in PAA-based moderate preoxidation for algal-laden water.
J Hazard Mater
January 2025
School of Civil & Environmental Engineering and Geography Science, Ningbo University, Ningbo 315211, China.
Moderate preoxidation is feasible for odor-producing algae treatments, usually requiring trade-offs in algal removal and integrity maintenance. However, dosing oxidants may cause internal oxidative homeostasis imbalances and secondary odorous metabolite responses, adding new trade-offs for moderate treatments. Peracetic acid (PAA)/Fe processes are promising strategies in moderate treatments and thus were applied to examine how to achieve the following three trade-offs: good algal removal, no odorant increases and no releases.
View Article and Find Full Text PDFObservational Characterization of the Retreatment Course of Patients With Thyroid Eye Disease.
J Neuroophthalmol
January 2025
Scheie Eye Institute (YC, TL, SW, TP, PAA, G-sY, CAB, MAT), University of Pennsylvania, Philadelphia, Pennsylvania; Divisions of Neuro-ophthalmology (MAT), Oculoplastics (CAB), and Biostatistics (PAA, G-sY), Kansas Health Science Center, Kansas College of Osteopathic Medicine; and Kansas Health Science Center (GM), Kansas College of Osteopathic Medicine, Kansas, Missouri.
Background: To characterize the retreatment course of patients with thyroid eye disease (TED), who had reactivation after initial therapy with teprotumumab.
Methods: This was a single-center longitudinal cohort study of patients who received an initial course of teprotumumab for active TED and were followed for at least 6 months. Reactivation was defined as the increase of proptosis of 2 mm or more or an increase in Clinical Activity Score (CAS) of two points or more, as adapted from the Optic-X study.
Intestinal distribution of anionic, cationic, and neutral polymer-stabilized nanocarriers measured with a lanthanide (europium) tracer assay.
J Control Release
December 2024
Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08544, USA. Electronic address:
Nanocarriers, more commonly called nanoparticles (NPs), have found increasing use as delivery vehicles which increase the oral bioavailability of poorly water-soluble and peptide therapeutics. Therapeutic bioavailability is commonly assessed by measuring plasma concentrations that reflect the absorption kinetics. This bioavailability is a convolution of the gastrointestinal distribution of the NP vehicle, the release rate of the encapsulated therapeutic cargo, and the absorption-metabolism-distribution kinetics of the released therapeutic.
View Article and Find Full Text PDFFinal, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
N Engl J Med
January 2025
From the Sandra and Edward Meyer Cancer Center (J.D.W.) and the Department of Medicine (J.D.W., M.A.P.), Weill Cornell Medicine, and Memorial Sloan Kettering Cancer Center (M.A.P.) - both in New York; Istituto Oncologico Veneto, IRCCS, Padua (V.C.-S.), European Institute of Oncology, IRCCS, Milan (P.Q.), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola (M.G.), University of Siena and the Center for Immuno-Oncology, University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.) - all in Italy; Maria Sklodowska-Curie National Institute of Oncology, Warsaw, Poland (P.R.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); University Hospital Essen, the German Cancer Consortium, the National Center for Tumor Diseases-West, the Research Alliance Ruhr, Research Center One Health, and University Duisburg-Essen - all in Essen, Germany (D.S.); the College of Medicine, Swansea University, Swansea (J.W.), Bristol Myers Squibb, Uxbridge (A.N.), and the Royal Marsden Hospital, London (J.L.) - all in the United Kingdom; the Department of Dermatology, University of Zurich, Zurich, Switzerland (R.D.); University Health Network Princess Margaret Cancer Centre, Toronto (M.O.B.), and Cross Cancer Institute, University of Alberta, Edmonton (J.W.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.G.H.), Westmead Hospital, Westmead, NSW (M.S.C.), Blacktown Hospital, Blacktown, NSW (M.S.C.), the Melanoma Institute Australia, University of Sydney (M.S.C., G.V.L.), Royal North Shore Hospital (G.V.L.), and Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (S.S.) - all in Australia; Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Marseille (C.G.-M.), and Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP) Dermato-oncology, Clinical Investigation Center, the Cancer Institute, AP-HP Nord Paris Cité, INSERM Unité 976, and St. Louis Hospital, Paris (C.L.) - all in France; the University of Colorado Cancer Center, Aurora (T.M.); Rogel Cancer Center, University of Michigan, Ann Arbor (C.D.L.); Hospital General Universitario Gregorio Marañon, Madrid (I.M-R.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); University Hospital Leuven and Leuven Cancer Institute, KU Leuven, Leuven, Belgium (P.S.); Bristol Myers Squibb, Princeton, NJ (C.R., M.A., M.P.B., W.W.); and Dana-Farber Cancer Institute, Boston (F.S.H.).
Background: Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.
View Article and Find Full Text PDFRandomized, placebo-controlled study on the effects of intravenous GSK3858279 (anti-CCL17) on a battery of evoked pain tests in healthy participants.
Clin Transl Sci
September 2024
Centre for Human Drug Research, Leiden, The Netherlands.
Article Synopsis
- CCL17 is a protein that affects inflammation and pain, and GSK3858279 is a new antibody that targets it to help with pain relief.
- A study was done on healthy adult males to see if GSK3858279 could reduce pain better than a placebo (a fake treatment).
- The results showed that there wasn’t a big difference in pain relief between GSK3858279 and the placebo, but it was safe and didn’t cause serious problems for the participants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!